H1 FY27 Net Profit Falls 23.8% YoY to ₹1.09 Cr as Revenue Declines 8.4% to ₹12.02 Cr
Nidan Laboratories announced its half-year results for the period ended September 30, 2026, reporting revenue from operations of ₹1,201.76 lakhs (₹12.02 Cr), down 8.4% YoY compared to ₹1,312.10 lakhs in H1 FY26. Net profit declined 23.8% YoY to ₹109.29 lakhs (₹1.09 Cr) from ₹143.37 lakhs in the previous corresponding half-year, resulting in an unannualized EPS of ₹0.79. However, on a sequential basis, net profit recovered sharply from ₹7.22 lakhs reported in H2 FY26 (ended March 31, 2026). Operating cash flow improved to ₹179.79 lakhs, but investing outflows of ₹290.24 lakhs (primarily driven by loans and advances) reduced cash and cash equivalents to ₹104.00 lakhs.
உச்சம் நம்பிக்கை
என்ன மாறியதுNidan Laboratories reported an 8.4% YoY decline in operational revenue and a 23.8% YoY drop in net profit for the half year ended September 30, 2026.
ஏன் இது முக்கியம்The drop in top-line and net earnings highlights persistent pricing and volume pressure in its core diagnostic business, while a substantial portion of assets remains tied up in non-core loans and investments.
Revenue from Operations (H1 FY27): ₹1,201.76 லட்சம்Net Profit (H1 FY27): ₹109.29 லட்சம்H1 FY27 Revenue vs TTM Revenue: ~24%Non-Current Investments: ₹2,000.00 லட்சம்Long-Term Loans and Advances: ₹3,549.98 லட்சம்
📅 குறுகிய காலம்Earnings contraction YoY may keep trading sentiment muted, though profitability has rebounded relative to the weak H2 FY26 period.
📈 நீண்ட காலம்Limited growth momentum; structural re-rating depends on the company's ability to protect core diagnostic margins against larger competitors and redeploy capital from loans back into center expansion.
⚠ அபாய எச்சரிக்கைகள்
- Elevated exposure to non-core assets with ₹35.50 Cr in long-term loans and advances and ₹20.00 Cr in non-current investments
- Intense competitive price-cutting from larger diagnostic chains in the Greater Mumbai region
👀 கவனிக்க வேண்டியவை
Monitor test volumes, price realizations against diagnostic peers in Greater Mumbai, and capital allocation toward non-core loans and advances in upcoming half-yearly disclosures.
